Literature DB >> 28074408

Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Andrew Van Tosh1, Kenneth J Nichols2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28074408     DOI： 10.1007/s12350-016-0771-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  24 in total

1.  Safety of regadenoson stress testing in patients with pulmonary hypertension.

Authors:  Victor M Moles; Thomas Cascino; Ashraf Saleh; Krasimira Mikhova; John J Lazarus; Michael Ghannam; Hong J Yun; Matthew Konerman; Richard L Weinberg; Edward P Ficaro; James R Corbett; Vallerie V McLaughlin; Venkatesh L Murthy
Journal:  J Nucl Cardiol       Date:  2016-11-28       Impact factor: 5.952

2.  Pulmonary Hypertension Overlap Syndromes: A Real Entity?

Authors:  Ori Ben-Yehuda; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

3.  Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.

Authors:  C Salgado-Garcia; A Jimenez-Heffernan; C Ramos-Font; J Lopez-Martin; E Sanchez-de-Mora; T Aroui; R Lopez-Aguilar; F Rivera-de-Los-Santos; C Ruiz-Frutos
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2016-05-06       Impact factor: 1.359

4.  Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension.

Authors:  Avi Shimony; Mark Jeffrey Eisenberg; Lawrence Glenn Rudski; Robert Schlesinger; Jonathan Afilalo; Dominique Joyal; Leonidas Dragatakis; Andrew Hirsch; Kim Boutet; Benjamin Daniel Fox; David Langleben
Journal:  Am J Cardiol       Date:  2011-05-19       Impact factor: 2.778

5.  Left ventricular myocardial ischemia in collagen disease associated with pulmonary hypertension: an evaluation by rest-stress gated SPECT and coronary angiography.

Authors:  Mohamed M El-Shafie; Shahenda S Salem; Abdel A Moghazi
Journal:  Nucl Med Commun       Date:  2011-07       Impact factor: 1.690

Review 6.  Optimising the management of pulmonary arterial hypertension patients: emergency treatments.

Authors:  M Delcroix; R Naeije
Journal:  Eur Respir Rev       Date:  2010-09

7.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

8.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Authors:  Christian F Opitz; Marius M Hoeper; J Simon R Gibbs; Harald Kaemmerer; Joanna Pepke-Zaba; J Gerry Coghlan; Laura Scelsi; Michele D'Alto; Karen M Olsson; Silvia Ulrich; Werner Scholtz; Uwe Schulz; Ekkehard Grünig; Carmine D Vizza; Gerd Staehler; Leonhard Bruch; Doerte Huscher; David Pittrow; Stephan Rosenkranz
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

9.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

10.  Causes and circumstances of death in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Vineesha Arelli; Omar A Minai; Jennie Newman; Nancy Bair; Gustavo A Heresi; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.